A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
NCT ID: NCT04608110
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
40 participants
INTERVENTIONAL
2020-10-30
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
NCT02005211
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.
NCT00844103
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551
NCT00860353
Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects
NCT00766012
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects
NCT00972049
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azacitidine + Cedazuridine
Drug: Azacitidine
Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration
Drug: Cedazuridine
Tablets for oral administration
ASTX030
In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASTX030
In Cycle 1 (28 days per cycle), single dose oral azacitidine formulations will be administered on day -3, followed by subcutaneous (SC) azacitidine on day 1, oral azacitidine formulations and cedazuridine tablets on day 2-7; in Cycle 2 and onward, oral azacitidine formulations and cedazuridine tablets will be administered on day 1-7
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of MDS (refractory anemia \[RA\], refractory anemia with ringed sideroblasts \[RARS\], refractory anemia with excess blasts \[RAEB\], refractory anemia with excess blasts in transformation \[RAEB-T\], or chronic myelomonocytic leukemia \[CMML\]) according to the French-American-British (FAB) classification Low-risk patients who fall under the risk category of low or intermediate-1 (Int-1) based on the International Prognostic Scoring System (IPSS) can be enrolled only if they are unlikely to respond to any other treatment or if they are currently being treated with azacytidine (AZA) injection
* Patients with an ECOG PS score of 0 or 1 or with an ECOG PS score of 2 due to primary disease-associated conditions
* Patients with adequate organ function as indicated below
1. Hepatic function: All of the following criteria must be satisfied.
* Total bilirubin ≤ 2.0 × upper limit of normal (ULN)
* Aspartate aminotransferase (AST) ≤ 2.5 × ULN
* Alanine aminotransferase (ALT) ≤ 2.5 × ULN
2. Renal function: Either of the following criteria must be satisfied.
* Serum creatinine ≤ 1.5 × ULN
* Creatinine clearance or glomerular filtration rate ≥ 50 mL/min
3. Respiratory function: percutaneous arterial oxygen saturation (SpO2) ≥ 90%
* Patients who are expected to survive for at least 3 months
* Patients who give written consent to participate in the trial using the informed consent form approved by the institutional review board
Exclusion Criteria
* Patients who have received chemotherapy, hormone therapy, antibody therapy, radiotherapy, or other exploratory anti-cancer treatments for the primary disease within 3 weeks prior to the first administration of the investigational medicinal product (IMP)
* Patients who have used any other IMP or any privately imported medicine within 4 weeks prior to the first administration of IMP
* Patients with heart disease of Class 3 or 4 according to the New York Heart Association classification
* Patients with uncontrolled systemic disease or active infection
* Patients with uncontrolled gastric or duodenal ulcer
* Patients with prior or current interstitial lung disease
* Patients with a history of surgical gastrectomy
* Patients with life-threatening conditions/symptoms, multiple organ failure, or other factors (including laboratory abnormalities) that, in the opinion of the investigator, are likely to affect their safety or the absorption and metabolism of AZA and cedazuridine (CED), or influence the trial evaluation
* Patients with other malignancies (except appropriately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ; prostate or breast cancer stabilized by endocrine therapies; and malignancies that have not relapsed for at least 1 year since the last successful treatment)
* Patients who are positive for HIV antibody, HBV-DNA, or HCV antibody
* Patients with any ≥ Grade 2 AE (except alopecia) associated with prior treatment of the primary disease. However, the parameters defined in inclusion criterion above are excluded.
* Patients who have undergone a highly invasive and extensive surgical procedure within 4 weeks prior to the first administration of IMP
* Patients who previously underwent or plan on undergoing hematopoietic stem cell transplantation
* Patients with a history of hypersensitivity to the active ingredient or any excipient of IMP
* Patients who are, in the opinion of the investigator, at high risk for being unable to comply with the trial protocol because of mental disorders or other medical conditions (alcohol/substance abuse or addiction)
* Pregnant or nursing female patients, or female patients with a positive pregnancy test at screening. Nursing patients cannot participate in the trial even if they discontinue breastfeeding. Female patients must undergo a pregnancy test to confirm that they are not pregnant at screening. However, a pregnancy test is not necessary for female patients without childbearing potential (ie, patients with a history of bilateral oophorectomy or hysterectomy or who have been postmenopausal for at least 12 months except for cases where menopause could be due to the effect of antineoplastic treatment).
* Sexually active males (except those with a history of bilateral orchiectomy) or females of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 3 months (males) and 6 months (females) after the last dose of IMP. If birth control is employed, 2 of the following precautions must be used: vasectomy, tubal ligation, intrauterine device, oral contraceptive, and condom (all methods approved or certified in Japan)
* Patients who, in the opinion of the investigator, are otherwise ineligible to participate in the trial
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taiho Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Taiho Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR
Taiho Pharmaceutical Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nippon Medical School Hospital
Bunkyō City, , Japan
Fukushima Medical University Hospital
Fukushima, , Japan
Saitama Medical University Hospital
Iruma, , Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, , Japan
Nagasaki University Hospital
Nagasaki, , Japan
Osaka City General Hospital
Osaka, , Japan
Kindai University Hospital
Sakai, , Japan
NTT Medical Center Tokyo
Shinagawa-Ku, , Japan
Tokyo Medical University Hospital
Shinjuku-Ku, , Japan
Yamagata University Hospital
Yamagata, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hematology
Role: primary
Hematology
Role: primary
Hematology
Role: primary
Hematology and Oncology
Role: primary
Hematology
Role: primary
Hematology
Role: primary
Hematology and Rheumatology
Role: primary
Hematology
Role: primary
Hematology
Role: primary
Hematology
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
418-102-00001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.